LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) von Chan, J., Geyer, S., Ou, F-S., Knopp, M., Behr, S., Zemla, T., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Trikalinos, N., Konda, B., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M.H., O'Reilly, E.M., Meyerhardt, J.A.

Volltext

4MO Is it time for a new staging system for colon adenocarcinoma (CA)? von Dasari, N.A., Jurdi, A., Nakamura, Y., Aushev, V., Kasi, P.M., Maddalena, G., Liu, M.C., Kopetz, S., Yoshino, T.

Volltext

520P Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase III FRESCO-2 t... von Garcia-Carbonero, R., Dasari, N.A., Eng, C., Tabernero, J., Yoshino, T., Hochster, H., Arnold, D., Randrian, V., Schelman, W., Dong, L., Yu, Z., Chen, L., Lonardi, S.

Volltext

363P Prevalence of acquired (acq) genomic alterations (GAs) after progression on anti-EGFR mAb (EGFRi) based therapy in metastatic colorectal cancer (mCRC): A systematic review and... von Raghav, K., Sun, R., Willis, J., Morris, V., Eluri, M., Dasari, N.A., Yuan, Y., Kopetz, S., Parseghian, C.

Volltext

587P Short lead time and high rates of concomitant radiographic recurrences for ctDNA-based minimal residual disease assays colorectal cancer (CRC) during surveillance: Results fro... von Eluri, M., Dasari, N.A., Maddalena, G., Bent, A., Pellatt, A.J., Balachandran Pillai, A., Alfaro-Munoz, K., Kell, R.J., Newhook, T., Uppal, A., Konishi, T., Morris, V., Kopetz, E.S.

Volltext

91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer von Gouda, M.A., Overman, M.J., Huang, H.J., Thomas, J., Dasari, N.A., Meric-Bernstam, F., Kopetz, S., Janku, F.

Volltext

1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progressio... von Chan, J., Geyer, S., Zemla, T., Knopp, M.V., Behr, S.C., Pulsipher, S., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Konda, B., Trikalinos, N., Shaheen, S., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M., O'Reilly, E.M., Meyerhardt, J.

Volltext

93P Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRES... von Kotani, D., Yoshino, T., Paulson, A.S., Masuishi, T., Hochster, H., Krauss, J., Sunakawa, Y., Takashima, A., Yamazaki, K., Kawakami, H., Nishina, T., Komatsu, Y., Esaki, T., Eng, C., Dasari, N.A., Yu, Z., Chen, L., Yang, T., Schelman, W., Satoh, T.

Volltext

458P Phase (Ph) I/Ib trial of fruquintinib (fru) in patients (pts) with advanced solid tumors: Preliminary results of the dose expansion (exp) cohort in refractory metastatic color... von Dasari, N.A., Wang-Gillam, A., Hubbard, J.M., Fernandez, A., Nanda, S., Kania, M., Schelman, W.R., Bekaii-Saab, T.S.

Volltext

526P Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age von Fernandez, M.E. Elez, Dasari, N.A., Lonardi, S., Eng, C., Garcia-Carbonero, R., Yoshino, T., Sobrero, A., Yao, J.C., Alfonso, P. García, Kocsis, J., Gracian, A. Cubillo, Bianchi, A. Sartore, Satoh, T., Randrian, V., Cremolini, C., Yang, Z., Schelman, W., Zhu, H., Chen, L., Tabernero, J.

Volltext

31P Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2 von Tabernero, J., Eng, C., Lonardi, S., Elez Fernandez, M.E., Yoshino, T., Sobrero, A., Yao, J.C., Sartore Bianchi, A., Randrian, V., Cremolini, C., Ghiringhelli, F., Hochster, H., Kasper-Virchow, S., Van Cutsem, E., Arnold, D., Tougeron, D., Zhu, H., Dong, C., Carton, I., Dasari, N.A.

Volltext

Safety and tolerability of surufatinib in western patients with solid tumours von Hamilton, E., Wang, J.S., Li, D., Dasari, N.A., Paulson, S., Cohn, A.L., Sauter, N.P., Kania, M., Kauh, J., Falchook, G.S.

Volltext

1393P - Safety and tolerability of surufatinib in western patients with solid tumours von Hamilton, E., Wang, J.S., Li, D., Dasari, N.A., Paulson, S., Cohn, A.L., Sauter, N.P., Kania, M., Kauh, J., Falchook, G.S.

Volltext

46MO FRESCO-2: A global / multiregional phase III clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with metastatic colorectal cancer von Yoshino, T., Dasari, N.A., Lonardi, S., Garcia-Carbonero, R., Elez Fernandez, M.E., Sobrero, A., Yao, J.C., García Alfonso, P., Kocsis, J., Cubillo Gracian, A., Sartore Bianchi, A., Randrian, V., Tomasek, J., Chong, G., Yang, Z., Schelman, W., Kania, M., Tabernero, J., Eng, C., Satoh, T.

Volltext

LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer von Dasari, N.A., Lonardi, S., Garcia-Carbonero, R., Fernandez, M.E. Elez, Yoshino, T., Sobrero, A.F., Yao, J.C., García-Alfonso, P., Kocsis, J., Gracian, A. Cubillo, Bianchi, A. Sartore, Satoh, T., Randrian, V., Tomasek, J., Chong, G., Yang, Z., Schelman, W., Kania, M., Tabernero, J., Eng, C.

Volltext

Active tracking during neoadjuvant therapy to improve outcomes of borderline arterial and locally advanced pancreatic cancer von Jahnsen, H.L., Pathanki, A., Powell-Brett, S., Isaac, J., Marudanayagam, R., Dasari, B., Bartlett, D., Muiesan, P., Mirza, D., Roberts, K., Sutcliffe, R., Chatzizacharias, N.A.

Volltext

Positive vein groove margin does not affect survival in patients undergoing pancreatoduodenectomy for early stages of pancreatic ductal adenocarcinoma von Ahuja, M., Pande, R., Chughtai, S.A., Roberts, K., Dasari, B., Bartlett, D., Marudanayagam, R., Mirza, D., Issac, J., Sutcliffe, R., Chatzizacharias, N.A.

Volltext